MAP2K7 and melanoma: BRAF mutations are seen in around 50% of patients with melanoma.[1,7] Response rates to BRAF/MEK inhibitor combination therapy approaches 70% in patients with metastatic melanoma.[8–10] When compared with either single-agent dabrafenib or vemurafenib, the combination of dabrafenib plus trametinib improves response rate, the duration of response, a progression-free survival, and the overall survival.[8,9] In our case, the patient did not tolerate vemurafenib monotherapy.